Tirzepatide for Weight Loss: What Research Shows

TL;DR

Tirzepatide for weight loss was tested in SURMOUNT-1, where adults without diabetes on the 15 mg weekly dose lost about 20.9 percent of body weight over 72 weeks in the primary analysis, and about 22.5 percent in the analysis that assumed the drug was taken as directed (Jastreboff et al., 2022). It is a dual agonist: one molecule turns on both the GIP and the GLP-1 receptor, unlike single GLP-1 drugs. For scale, semaglutide produced about 14.9 percent mean weight loss in STEP 1 (Wilding et al., 2021), and a head-to-head diabetes trial, SURPASS-2, favored tirzepatide (Frias et al., 2021). Weight loss tends to slow over time (Horn et al., 2025), and much of it returns after stopping (Aronne et al., 2024). Trials report dose ranges. This page does not prescribe. Any personal dose is a clinical decision.

What does tirzepatide do for weight loss?

Tirzepatide is a once-weekly peptide that turns on two gut-hormone receptors at once, and in trials this dual action produced larger average weight loss than older single-receptor drugs (Jastreboff et al., 2022).

It is a single molecule that acts on both the GIP receptor and the GLP-1 receptor. These are the receptors for two natural "incretin" hormones your gut releases after eating. By acting on both, tirzepatide lowers appetite and changes how the body handles food and blood sugar. The main weight-loss trial, SURMOUNT-1, tested this in adults with obesity or with overweight plus a weight-related condition, without diabetes (Jastreboff et al., 2022). Tirzepatide is approved for chronic weight management under the brand Zepbound and for type 2 diabetes under the brand Mounjaro (FDA, 2023).

How does tirzepatide work in the body? (GIP plus GLP-1)

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means one molecule activates two incretin pathways that reduce appetite and slow how fast the stomach empties (Jastreboff et al., 2022).

The GLP-1 pathway is the same one used by semaglutide (Wilding et al., 2021). It lowers hunger signals and slows gastric emptying. Tirzepatide adds the GIP pathway on top of that. The combination of both receptors is what sets tirzepatide apart from GLP-1-only drugs.

How much weight did people lose in the tirzepatide trials?

In SURMOUNT-1, participants on the highest weekly dose lost about 20.9 percent of their body weight over 72 weeks in the primary analysis, and about 22.5 percent in the analysis that assumed full adherence (Jastreboff et al., 2022).

SURMOUNT-1 ran for 72 weeks and reported that weight loss rose with the dose (Jastreboff et al., 2022). The trial reported two analyses. The treatment-regimen estimand counts everyone from randomization, including people who stopped the drug, and gave the more conservative numbers. The efficacy estimand estimates the effect if the drug is taken as directed, and gave the higher numbers, including the widely quoted 22.5 percent for the 15 mg arm. The numbers below are trial arms, not a plan for any person.

### Doses studied in SURMOUNT-1 (research-reported, not a recommendation)

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Doses were reached through gradual titration over a 20-week build-up. These are study arms, not a dosing guide.

How does tirzepatide compare to semaglutide?

Reported weight loss was larger for tirzepatide, and a head-to-head diabetes trial favored it, though the main weight-loss results come from separate trials (Frias et al., 2021; Jastreboff et al., 2022; Wilding et al., 2021).

SURPASS-2 compared tirzepatide against semaglutide 1 mg in adults with type 2 diabetes and reported greater reductions in both blood sugar and body weight with tirzepatide (Frias et al., 2021). For weight specifically, tirzepatide's SURMOUNT-1 result (about 20.9 percent at 15 mg in the primary analysis) was higher than semaglutide's STEP 1 result (about 14.9 percent), but these were different trials with different participants (Jastreboff et al., 2022; Wilding et al., 2021). A later head-to-head obesity trial, SURMOUNT-5, also reported greater weight loss with tirzepatide than semaglutide (Aronne et al., 2025).

For a fuller side-by-side, see /tirzepatide-vs-semaglutide.

What are realistic expectations on tirzepatide?

Average losses in trials are large, but results vary by person, weight loss slows over time, and a large share returns after stopping (Horn et al., 2025; Aronne et al., 2024).

The trial figures are averages. Some participants lost much more, some much less. Weight loss on tirzepatide also tends to reach a plateau after a period of treatment. A post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 reported that most participants had reached a weight plateau by around week 72 (Horn et al., 2025). Part of the difficulty in going further is adaptive thermogenesis, where the body lowers its energy use after weight loss and works against further loss (Rosenbaum and Leibel, 2010). And in SURMOUNT-4, people who stopped tirzepatide regained much of their lost weight, while those who continued kept it off (Aronne et al., 2024). The same pattern shows up with semaglutide, where about two-thirds of lost weight returned within a year of stopping (Wilding et al., 2022).

What did trials report about side effects?

The most commonly reported effects in tirzepatide trials were gastrointestinal, such as nausea, diarrhea, and constipation, mostly mild to moderate and more common during dose increases (Jastreboff et al., 2022).

In SURMOUNT-1, these gastrointestinal events were the most common reason participants reduced or stopped treatment, and they clustered around the periods when the dose was raised (Jastreboff et al., 2022). This page reports trial findings and is not medical advice. A qualified clinician should review your full history before any use.

What doses were studied, and what does that mean for me?

SURMOUNT-1 studied weekly subcutaneous doses of 5, 10, and 15 mg after a gradual build-up, but the right dose for any individual is a clinical decision this page cannot make (Jastreboff et al., 2022).

Trials use fixed dose arms and slow titration to limit side effects. That is research design, not personal instruction. What is safe or appropriate for one person depends on their health, other conditions, and clinician judgment. This page does not tell you what to take, when, or how.